ArticleJournal of inflammation (London, England)2026
FOXD2-AS1/miR-185-5p/CDC42 axis in chronic obstructive pulmonary disease: clinical significance and mechanistic insights.
Article in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLong non-coding RNA (lncRNA), a key molecule within gene expression regulatory network, is important in various respiratory diseases. This study assessed the expression changes and regulatory mechanism of lncRNA FOXD2-AS1 in chronic obstructive pulmonary disease (COPD). MATERIALS AND
methodsTwo hundred COPD patients were enrolled, comprising 100 with AECOPD and 100 with stable COPD. 16HBE cells were exposed to cigarette smoke extract (CSE) to simulate disease conditions in vitro. Relative mRNA levels were measured via RT-qPCR. Cell function, including cell proliferation, apoptosis and inflammation, was assessed. Target binding genes were predicted using online tools, with their functions annotated via GO and KEGG analysis.
resultsBoth stable COPD patients and AECOPD patients had significantly higher serum FOXD2-AS1 levels than healthy controls, with the highest values in AECOPD. It can differentiate stable COPD from healthy controls and AECOPD, and increased gradually with COPD stage progression. Silencing FOXD2-AS1 afforded protection against apoptotic and inflammatory phenotype induced by CSE in 16HBE cells. FOXD2-AS1 sponges miR-185-5p, which were downregulated in clinical serum samples and cell models. miR-185-5p downregulation reversed the effects of FOXD2-AS1 silencing on cell apoptosis and inflammation. CDC42, a downstream target of miR-185-5p, was upregulated in COPD patients and cell models, and negatively related to serum miR-185-5p levels. CDC42 reversed the role of FOXD2-AS1/ miR-185-5p in CSE-exposed 16HBE cells.
conclusionsSerum FOXD2-AS1 was markedly upregulated in COPD patients, with close correlation to disease severity. The FOXD2-AS1/miR-185-5p/CDC42 axis may contribute to COPD pathogenesis by mediating bronchial epithelial cell apoptosis and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.